<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985318</url>
  </required_header>
  <id_info>
    <org_study_id>V01-19052020</org_study_id>
    <nct_id>NCT04985318</nct_id>
  </id_info>
  <brief_title>Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP</brief_title>
  <acronym>REACT-2020</acronym>
  <official_title>Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this national, prospective, multi-centre observational study is to describe&#xD;
      the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a&#xD;
      real-world setting, and identify predicting factors in iTTP-patients with regard to&#xD;
      persistent autoimmune activity, therapy guidance and risk of complications. The rational is&#xD;
      to develop new treatment algorithms that optimize overall patient outcome and reduce&#xD;
      treatment cost.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment of aTTP with caplacizumab</measure>
    <time_frame>Enrollment</time_frame>
    <description>Description of the prescription rationale and practice of caplacizumab in the treatment of aTTP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of caplacizumab</measure>
    <time_frame>Enrollment</time_frame>
    <description>Documentation of the efficacy of caplacizumab in the treatment of aTTP outside of clinical trials (real-world data)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for complications</measure>
    <time_frame>Enrollment</time_frame>
    <description>Identification of risk factors for complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for adverse outcomes</measure>
    <time_frame>Enrollment</time_frame>
    <description>Identification of risk factors for adverse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for persistent autoimmune activity</measure>
    <time_frame>Enrollment</time_frame>
    <description>Identification of risk factors for persistent autoimmune activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters for therapy guidance</measure>
    <time_frame>Enrollment</time_frame>
    <description>Identification of parameters that guide duration and regimen of caplacizumab treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of caplacizumab on adjunct treatments with PEX</measure>
    <time_frame>Enrollment</time_frame>
    <description>Descriptions of duration and dose of therapeutic plasma exchange therapy (PEX), number of procedure-associated adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of caplacizumab on adjunct treatments</measure>
    <time_frame>Enrollment</time_frame>
    <description>Descriptions of the effect of caplacizumab on dose, duration and number and severity of adverse events of glucocorticoids</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Acquired Thrombotic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Registergroup</arm_group_label>
    <description>Patients with acquired Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cablivi®</intervention_name>
    <description>Intervention with Cablivi® take place outside of the study</description>
    <arm_group_label>Registergroup</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female subjects with confirmed diagnosis of an acute episode of aquired thrombotic&#xD;
        thrombocytopenic purpura, who have been treated with one dose of caplacizumab.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenic&#xD;
             purpura&#xD;
&#xD;
          -  Treatment with at least one single dose of caplacizumab (10 mg i.v. or s.c.)&#xD;
&#xD;
          -  Male or female patients ≥ 18 years of age&#xD;
&#xD;
          -  signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hereditary thrombotic thrombocytopenic purpura&#xD;
&#xD;
          -  disability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linus Völker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department II of Internal Medicine, University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linus Völker, MD</last_name>
    <phone>+49 221 478 86285</phone>
    <email>linus.voelker@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucas Kühne, MD</last_name>
    <email>lucas.kuehne@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linus Völker, MD</last_name>
      <phone>+49 221 478 86285</phone>
      <email>linus.voelker@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Lucas Kühne, MD</last_name>
      <email>lucas.kuehne@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Linus Völker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Brinkkötter, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucas Kühne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Paul Brinkkoetter</investigator_full_name>
    <investigator_title>Prof. MD, Consultant in Nephrology</investigator_title>
  </responsible_party>
  <keyword>aTTP</keyword>
  <keyword>caplacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

